---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-075345"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:26:43.212443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events

## Summary
- Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.
- In monotherapy, 3 patients with baseline HBsAg <50 IU/mL had 0.7-1.4 log10 declines durable up to 8 months.
- Combination group (8 patients) had mean HBsAg reduction >1 log10 at 6 months, persisting to 1.15 log10 at 8 months.
- Robust T cell response with marked CD8+ predominance observed; enrollment complete at 55 patients.
- Updated interim analysis for all patients at 6-month follow-up expected end of 2022; new trial dosing expected Q3 2022.

## SEC filing metadata
- accession: 0001104659-22-075345
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/0001104659-22-075345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/tm2219878d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-075345
- JSON: https://secwatch.observer/filing/0001104659-22-075345.json
- Plain text: https://secwatch.observer/filing/0001104659-22-075345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.